Show simple item record

dc.contributor.authorMaouche, Nadjoua
dc.contributor.authorKishore, Bhuvan
dc.contributor.authorBhatti, Zara
dc.contributor.authorBasu, Supratik
dc.contributor.authorKarim, Farheen
dc.contributor.authorSundararaman, Sharadha
dc.contributor.authorCollings, Freya
dc.contributor.authorTseu, Bing
dc.contributor.authorLeary, Heather
dc.contributor.authorRyman, Noel
dc.contributor.authorReddy, Udaya
dc.contributor.authorVallance, Grant
dc.contributor.authorKothari, Jaimal
dc.contributor.authorRamasamy, Karthik
dc.date.accessioned2023-02-28T12:03:43Z
dc.date.available2023-02-28T12:03:43Z
dc.date.issued2022-07-07
dc.identifier.citationMaouche N, Kishore B, Bhatti Z, Basu S, Karim F, Sundararaman S, et al. (2022) Panobinostat in combination with bortezomib and dexamethasone in multiply relapsed and refractory myeloma; UK routine care cohort. PLoS ONE 17(7): e0270854. https://doi.org/10.1371/journal.pone.0270854en
dc.identifier.issn1932-6203en
dc.identifier.pmid35797277 (pubmed)
dc.identifier.doi10.1371/journal.pone.0270854en
dc.identifier.urihttp://hdl.handle.net/2436/625128
dc.description© 2023 The Authors. Published by PLoS. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: https://doi.org/10.1371/journal.pone.0270854en
dc.description.abstractThe combination of panobinostat, bortezomib and dexamethasone (PanBorDex) is available as a treatment option for relapsed refractory multiple myeloma (RRMM) based on the PANORAMA-1 trial which investigated this triplet in early relapse. In routine clinical care, PanBorDex is used primarily in later relapses and is commonly administered in attenuated dosing schedules to mitigate the treatment-related toxicity. We set out to evaluate efficacy and safety outcomes with PanBorDex later in the disease course and evaluate the role of attenuated dosing schedules. This was a retrospective evaluation of patients treated in routine clinical practice between 2016–2019 across seven heamatology centres in the UK; patients who received at least one dose of PanBorDex were eligible for inclusion. The dosing schedule of panobinostat (10mg, 15mg or 20mg, twice or three times a week) and bortezomib (0.7mg/m2, 1mg/m2 or 1.3mg/m2 once or twice weekly) was as per treating physician choice. Patients received treatment until disease progression or unacceptable toxicity. The primary outcome is response rates according to IMWG criteria. Key secondary endpoints include progression-free survival (PFS) and overall survival (OS). Other secondary endpoints include rates of adverse events according to CTCAE criteria. In total, 61 patients were eligible for inclusion and received PanBorDex primarily as ≥5th line of treatment. One third of patients received PanBorDex at full dose, for the remaining two thirds, treatment was given in reduced dose intensities. The overall response rate was 44.2%, including 14.7% very good partial response (VGPR) rates; 68.8% of patients derived clinical benefit with stable disease or better. The median PFS was 3.4 months; non-refractory patients and those who achieved VGPR benefited from prolonged PFS of 11.4 months and 17.7 months, respectively. The median OS was 9.5 months. The triplet was associated with 45% and 18% incidence of grade 3–4 thrombocytopenia and diarrhea, respectively.en
dc.formatapplication/pdfen
dc.languageeng
dc.language.isoenen
dc.publisherPublic Library of Scienceen
dc.relation.urlhttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0270854en
dc.rightsLicence for published version: Creative Commons Attribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectpanobinostaten
dc.subjectbortezomiben
dc.subjectdexamethasoneen
dc.subjectmyelomaen
dc.subject.meshHumans
dc.subject.meshMultiple Myeloma
dc.subject.meshDexamethasone
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshRetrospective Studies
dc.subject.meshBortezomib
dc.subject.meshUnited Kingdom
dc.subject.meshPanobinostat
dc.titlePanobinostat in combination with bortezomib and dexamethasone in multiply relapsed and refractory myeloma; UK routine care cohorten
dc.typeJournal articleen
dc.identifier.eissn1932-6203
dc.identifier.journalPLoS ONEen
dc.date.updated2023-02-27T10:39:18Z
dc.contributor.institutionDepartment of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
dc.identifier.callnumbere0270854
pubs.place-of-publicationUnited States
dc.date.accepted2022-06-20
rioxxterms.funderUniversity of Wolverhamptonen
rioxxterms.identifier.projectUOW28022023SBen
rioxxterms.versionVoRen
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/en
rioxxterms.licenseref.startdate2023-02-28en
dc.source.volume17
dc.source.issue7
dc.source.beginpage1
dc.description.versionPublished version
refterms.dateFCD2023-02-28T12:03:32Z
refterms.versionFCDVoR
refterms.dateFOA2023-02-28T12:03:44Z


Files in this item

Thumbnail
Name:
Panobinostat in combination with ...
Size:
843.4Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Licence for published version: Creative Commons Attribution 4.0 International
Except where otherwise noted, this item's license is described as Licence for published version: Creative Commons Attribution 4.0 International